Adults 18 to 99, any sex, with Social Anxiety Disorder (SAD). Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Measurement of Intervention Credibility Assessed With the Credibility Score, at BaselinePrimary· Baseline
The Credibility/Expectation Questionnaire (CEQ) asks about the improvements that subjects believe will be achieved as a result of treatment, and how believable, convincing,and logical the treatment seems.It contains six items rated on a 1-9 scale. The first three items load onto the credibility factor. Higher scores suggest better experience, lower scores suggest poor experience.Credibility score is calculated by taking the sum of score of the first 3 items of the CEQ scale ranging from 3 to 27.
Group
Value
95% CI
BVR-100
18
± 4.31
BES-100
15.4
± 4.57
Measurement of Intervention Credibility Assessed With the Credibility Score, at Week 6Primary· 6 weeks
The Credibility/Expectation Questionnaire (CEQ) asks about the improvements that subjects believe will be achieved as a result of treatment, and how believable, convincing,and logical the treatment seems.It contains six items rated on a 1-9 scale. The first three items load onto the credibility factor. Higher scores suggest better experience, lower scores suggest poor experience.Credibility score is calculated by taking the sum of score of the first 3 items of the CEQ scale ranging from 3 to 27.
Group
Value
95% CI
BVR-100
18.9
± 5.37
BES-100
12.3
± 6.56
Measurement of Intervention Credibility Assessed With the Credibility Score, at Week 8Primary· 8 weeks
The Credibility/Expectation Questionnaire (CEQ) asks about the improvements that subjects believe will be achieved as a result of treatment, and how believable, convincing,and logical the treatment seems.It contains six items rated on a 1-9 scale. The first three items load onto the credibility factor. Higher scores suggest better experience, lower scores suggest poor experience.Credibility score is calculated by taking the sum of score of the first 3 items of the CEQ scale ranging from 3 to 27.
Group
Value
95% CI
BVR-100
18.7
± 6.31
BES-100
13.7
± 7.68
Measurement of Intervention Credibility Assessed With Expectancy Score, at BaselinePrimary· Baseline
The Credibility/Expectation Questionnaire (CEQ) asks about the improvements that subjects believe will be achieved as a result of treatment, and how believable, convincing,and logical the treatment seems.It contains six items rated on a 1-9 scale. The final three items load onto the expectancy factor. Higher scores suggest better experience, lower scores suggest poor experience.Expectancy score is calculated by taking the sum of score of the last 3 items of the CEQ scale ranging from 3 to 27.
Group
Value
95% CI
BVR-100
17.1
± 4.43
BES-100
14.8
± 3.24
Measurement of Intervention Credibility Assessed With the Expectancy Score, at Week 6Primary· 6 weeks
The Credibility/Expectation Questionnaire (CEQ) asks about the improvements that subjects believe will be achieved as a result of treatment, and how believable, convincing,and logical the treatment seems.It contains six items rated on a 1-9 scale. The final three items load onto the expectancy factor. Higher scores suggest better experience, lower scores suggest poor experience.Expectancy score is calculated by taking the sum of score of the last 3 items of the CEQ scale ranging from 3 to 27.
Group
Value
95% CI
BVR-100
15.4
± 5.75
BES-100
11.6
± 7.14
Measurement of Intervention Credibility Assessed With the ExpectancyScore, at Week 8Primary· 8 weeks
The Credibility/Expectation Questionnaire (CEQ) asks about the improvements that subjects believe will be achieved as a result of treatment, and how believable, convincing,and logical the treatment seems.It contains six items rated on a 1-9 scale. The final three items load onto the expectancy factor. Higher scores suggest better experience, lower scores suggest poor experience.Expectancy score is calculated by taking the sum of score of the last 3 items of the CEQ scale ranging from 3 to 27.
Group
Value
95% CI
BVR-100
15.3
± 6.21
BES-100
13.6
± 7.47
Subject Retention Rate at Week 6Secondary· 6 weeks
Subject retention in each group were assessed by percentage of subjects who remain on the study at Week 6
Group
Value
95% CI
BVR-100
96
BES-100
100
Subject Retention Rate at Week 8Secondary· 8 weeks
Subject retention in each group were assessed by percentage of subjects who remain on the study at Week 8
Group
Value
95% CI
BVR-100
96
BES-100
100
Summary of Time-on-TaskSecondary· 8 weeks
Time-on-task, averaged over all VR sessions from baseline to Week 8/EOS. Time on task will be automatically recorded by the VR system after each session.
Group
Value
95% CI
BVR-100
4.97
± 1.886
BES-100
6.59
± 0.359
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to 8 Weeks.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Other recruiting trials for Social Anxiety Disorder (SAD)
Currently open trials in the same condition.
NCT07228143 — Stepped Care Treatment for Anxiety Resilience
· NA
· recruiting
NCT07466277 — Intermittent Theta Burst Stimulation of the Prefrontal Cortex in Social Anxiety Disorder
· NA
· recruiting
NCT07533812 — AI-Assisted 4-Week Psychodynamic Therapy and Cognitive Behavioral Therapy Via Smartphone for Social Anxiety: A Randomize
· NA
· active not recruiting
NCT06901128 — The Covideo Study - a Trial of Cognitive Therapy for Social Anxiety Disorder in Youth, Comparing Screen to Office Delive
· NA
· recruiting
NCT06805565 — A Study of ONO-1110 in Patients With Social Anxiety Disorder
· Phase 2
· active not recruiting
Other Sumitomo Pharma America, Inc. trials
Trials by the same sponsor.
NCT06891885 — A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years
· Phase 1, PHASE2
· recruiting
NCT06753331 — A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's
· Phase 1, PHASE2
· recruiting
NCT06517940 — A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)
· active not recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sumitomo Pharma America, Inc.
Last refreshed: 12 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06037668.